Bladder cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• ERK 0
• MYC 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 53+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

  NCT04902040· M.D. Anderson Cancer Center· Updated 30 Apr 2026

  “PI requested.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

  NCT04064190· MedPacto, Inc.· Updated 9 Dec 2024

  “Changing trial strategy”Registry text, quoted unchanged. Source

• Terminated

  Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

  NCT03809624· Inhibrx Biosciences, Inc· Updated 23 Oct 2024

  “Program terminated due to lack of meaningful efficacy signal.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

  NCT05574504· AdventHealth· Updated 1 Aug 2024

  “PI Decision based on no enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

  NCT03150836· Terence Friedlander, MD· Updated 19 Oct 2017

  “Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Hoffmann-La Roche· Source

• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

  NCT04579224· National Cancer Institute (NCI)· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

  NCT03711032· Merck Sharp & Dohme LLC· Source

• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· AstraZeneca· Source

• Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

  NCT07625527· Tianjin Medical University Second Hospital· Source

• Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Merck Sharp & Dohme LLC· Source

• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Merck Sharp & Dohme LLC· Source

• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

  NCT05327530· EMD Serono Research & Development Institute, Inc.· Source

• Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

  NCT06439836· National Cancer Institute (NCI)· Source

• TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

  NCT07038928· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 93
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 76
• Genome-Wide Association Study 18

• Deep learning-based multiomics integration identifies AI-defined tissue regions associated with cancer-associated fibroblast enrichment and chemoresistance in muscle-invasive bladder cancer.

  Funct Integr Genomics, Oct 2026

• Task-agnostic explainable contrastive learning model for malignant cell detection in urine cytology.

  Biomed Phys Eng Express, Sept 2026

• Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.

  Biosensors (Basel), Aug 2026

• Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50.

  World J Urol, Aug 2026

• Deep learning-assisted detection of lymph node metastases in bladder cancer.

  Diagn Pathol, Aug 2026

• MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.

  Nat Commun, Aug 2026

• UCtracker: A Deep Learning-Based DNA Methylation Model for Noninvasive Diagnosis and Recurrence Surveillance of Urothelial Carcinoma in a Prospective Study.

  Adv Sci (Weinh), Aug 2026

• Deep learning approaches for predicting response to neoadjuvant chemotherapy in muscle invasive bladder cancer: A systematic review.

  Urol Oncol, Jul 2026

• Accurate focal-plane selection is crucial for artificial intelligence assessment of three-dimensional urine cytology specimens for bladder cancer screening and surveillance.

  Cancer Cytopathol, Jul 2026

• [MRI-based deep learning model for preoperative prediction of urothelial carcinoma with variant histology of bladder: a retrospective, multicenter study].

  Zhonghua Wai Ke Za Zhi, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.